Type 2 Diabetes Mellitus Clinical Trial
— PHROfficial title:
Effect of Monitoring and Education of Step Number Assessed by Smartphone Application on Blood Glucose, Weight and Blood Pressure in Patients With Type 2 Diabetes
Verified date | March 2019 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, investigators measured the number of steps, blood pressure, blood glucose, and weight in daily life through the smartphone personal health record application for patients with type 2 diabetes. The efficacy of text message intervention, which encourages an increase in the number of steps per week for 12 weeks, on an increase in the number of daily steps and changes in glucose levels, weight, and blood pressure will be investigated. Also, the durability of intervention will be checked after 12 weeks of intervention ending.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | November 30, 2019 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 69 Years |
Eligibility |
Inclusion Criteria: - Patients with Type 2 diabetes aged 20-69 years - Patients with a HbA1c of less than 8.5% measured during screening (may be replaced by a test value within 3 months of screening visit ) - Patients who have not been prescribed diabetic medication for the past 4 weeks or who have taken more than one oral hypoglycemic agent for more than 12 weeks at a certain dose - BMI = 23 kg/m2 - Available for use Samsung Galaxy S4 or later Android smartphone and wireless internet - Patients who voluntarily agreed to participate in this clinical study Exclusion Criteria: - Diabetes other than type 2 diabetes, including type 1 diabetes, gestational diabetes - Patients who are taking insulin or GLP-1 agonist other than oral hypoglycemic agent - Patients with uncontrolled chronic liver disease - Patients with acute kidney injury - Patients with psychological disorder - Patients who are taking weight lowering agent - Patients with alcohol or drug addiction within the last 3 - Patients who are taking systemic steroid - Patients who are breastfeeding or pregnant - Patients who did not voluntarily agree to the study - Patients who are unsuitable for participation in clinical research |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in daily step count after 12 weeks of intervention | change in daily step count after 12 weeks of intervention | Week 12 | |
Secondary | mean daily step count after 12 weeks of intervention | mean daily step count after 12 weeks of intervention | Week 12 | |
Secondary | the proportion of patients who reach participant-day during the 12 weeks of intervention | the proportion of patients who reach participant-day during the 12 weeks of intervention The participant-day means the day the participant reach thier upper group of daily step count | Week 12 | |
Secondary | mean daily step count at Week 24 | mean daily step count at Week 24 | Week 24 | |
Secondary | the proportion of patients who reach participant-day during the Week 13-24 | the proportion of patients who reach participant-day during the Week 13-24 | Week 24 | |
Secondary | the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia | the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia | Week 12 | |
Secondary | the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia | the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia | Week 24 | |
Secondary | HbA1c levels | HbA1c levels (%) | Week 12 | |
Secondary | HbA1c levels | HbA1c levels (%) | Week 24 | |
Secondary | Fasting glucose levels | Fasting glucose levels (mg/dL) | Week 12 | |
Secondary | Fasting glucose levels | Fasting glucose levels (mg/dL) | Week 24 | |
Secondary | Body weight | Body weight (kg) | Week 12 | |
Secondary | Body weight | Body weight (kg) | Week 24 | |
Secondary | Blood pressure | Blood pressure (mmHg) | Week 12 | |
Secondary | Blood pressure | Blood pressure (mmHg) | Week 24 | |
Secondary | IPAQ (international physical activity questionnaire) score | IPAQ (international physical activity questionnaire) score are consisted of 7 questions regarding frequency of exercise, intensity of exercise, and duration of exercise. Using its automatic report, the results can be calculated as weekly physical activity level (low, intermediate, high). | Week 12 | |
Secondary | IPAQ (international physical activity questionnaire) score | IPAQ (international physical activity questionnaire) score are consisted of 7 questions regarding frequency of exercise, intensity of exercise, and duration of exercise. Using its automatic report, the results can be calculated as weekly physical activity level (low, intermediate, high). | Week 24 | |
Secondary | number of recordings on personal health record application | number of recordings on personal health record application | Week 12 | |
Secondary | number of recordings on personal health record application | number of recordings on personal health record application | Week 24 | |
Secondary | Total cholesterol | Total cholesterol (mg/dL) | Week 12 | |
Secondary | Total cholesterol | Total cholesterol (mg/dL) | Week 24 | |
Secondary | High-density lipoprotein cholesterol | High-density lipoprotein cholesterol (mg/dL) | Week 12 | |
Secondary | High-density lipoprotein cholesterol | High-density lipoprotein cholesterol (mg/dL) | Week 24 | |
Secondary | Triglycerides | Triglycerides (mg/dL) | Week 12 | |
Secondary | Triglycerides | Triglycerides (mg/dL) | Week 24 | |
Secondary | low-density lipoprotein cholesterol | low-density lipoprotein cholesterol (mg/dL) | Week 12 | |
Secondary | low-density lipoprotein cholesterol | low-density lipoprotein cholesterol (mg/dL) | Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |